Compare Marvell Technology Inc (MRVL) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Vaxcyte Inc. Common Stock — how do they compare? Marvell Technology Inc trades at $238.5 (market cap $241.50B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Marvell Technology Inc is far larger — about 23× Vaxcyte Inc. Common Stock's market cap, and Marvell Technology Inc pays a 0.09% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 43 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MRVL | PCVX | |
|---|---|---|
Market Cap | $241.50B | $10.51B |
Volume | 18,287,907 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $316.43 | $73.82 |
52-Week Low | $73.73 | $40.32 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $242.86B | $9.14B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $245.28, down 7.74% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $327.86 implying significant upside. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $1.1, and projects robust revenue growth, particularly in its custom AI chip business, which is forecast to more than double by fiscal 2028. Despite a net loss in 2025, improving operating cash flow and a strong gross margin of 52.21% highlight underlying operational strength.
The outlook for MRVL is positive, driven by AI-driven demand in data centers and custom silicon deals with hyperscalers like Google, though high valuation multiples (P/E of 88.98) and execution risks in scaling custom chip production pose challenges. Investor sentiment remains bullish, with 83.79% of analysts rating the stock a buy, but volatility near all-time highs and competitive pressures warrant caution.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
